Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. HUMA
8. NVDA
9. CRWV
10. CME

Go back to Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

Citi Reiterates Buy Rating on Arcturus Therapeutics (ARCT)

May 29, 2024 12:57 PM UTC

Citi analyst Yigal Nochomovitz reiterated a Buy rating and $48.00 price target on Arcturus Therapeutics (NASDAQ: ARCT).

The analyst comments "Its always tough to draw conclusions from such small data sets (N=4) and ever more so in an open-label, uncontrolled setting, where the... More